Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Kidney cancer

Overall survival is an unsuitable primary end point

Nature Reviews Urology volume 7, pages 367–368 (2010)Cite this article

Subjects

Final results of the CALGB 90206 and AVOREN trials have failed to demonstrate an overall survival benefit for bevacizumab plus interferon compared to interferon monotherapy in patients with metastatic renal cell carcinoma. Progression-free survival or objective response rate might be more suitable primary end points in phase III trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).

    Article  CAS  Google Scholar 

  2. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).

    Article  CAS  Google Scholar 

  3. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).

    Article  Google Scholar 

  4. Rini, B. I. et al. Bevacizumab plus interferon alpha compared with interferon alpha monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008).

    Article  CAS  Google Scholar 

  5. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).

    Article  CAS  Google Scholar 

  6. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).

    Article  CAS  Google Scholar 

  7. Sternberg, C. N. et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) [abstract 2347]. J. Clin. Oncol. 27 (15s), 5021 (2009).

    Google Scholar 

  8. Rini, B. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137–2143 (2010).

    Article  CAS  Google Scholar 

  9. Escudier, B. J. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144–2150 (2010).

    Article  CAS  Google Scholar 

  10. Rini, B. et al. Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib [abstract 312]. ASCO 2010 Genitourinary Cancers Symposium [online], (2010).

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Oncology and Endocrinology, The University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy

    Giuseppe Di Lorenzo & Carlo Buonerba

Authors
  1. Giuseppe Di Lorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Buonerba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Di Lorenzo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Lorenzo, G., Buonerba, C. Overall survival is an unsuitable primary end point. Nat Rev Urol 7, 367–368 (2010). https://doi.org/10.1038/nrurol.2010.84

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.84

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing